Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

The RAS family of proteins are one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way.